View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-2026-jp-morgan-healthcare-conference-302648108.html ...
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (UPB) (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz ...
Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...
PALO ALTO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today ...
Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced that Nate Fernhoff, Ph.D., Orca Bio’s co-founder and ...
MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results